Maplelane Capital’s Amgen AMGN Stock Holding History

Maplelane Capital’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-189,000	Closed	-$35.9M	–	118
2019 Q1	$35.9M	Sell	189,000 -106,000	-36%	-$20.2M	1%	30
2018 Q4	$57.4M	Buy	+295,000	New	+$57.6M	1.67%	16

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Maplelane Capital's AMGN Position: Q2 2019 in Review

Maplelane Capital sold out of Amgen (AMGN) in Q2 2019, closing a stake of 1 share.

Maplelane Capital first reported a position in AMGN in Q4 2018 and held it in 2 quarters. The position peaked at $0 in Q1 2019. 1,865 funds tracked by Wall St. Rank hold AMGN as of Q2 2019.

Maplelane Capital reported no remaining Amgen position as of Q2 2019 after selling out during the quarter.
Maplelane Capital sold 1 Amgen share in Q2 2019.
Maplelane Capital first reported a position in Amgen in Q4 2018 and held it in 2 quarters.
Maplelane Capital's Amgen position peaked at $0 in Q1 2019.
1,865 funds tracked by Wall St. Rank held Amgen as of Q2 2019.

Based on Maplelane Capital's 13F filing for Q2 2019, filed 14 Aug 2019.